Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR3 | O15455 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12678220 | 0.88 | BCKDK (0.38) | BCKDKRAB9AKDM4EALOX5MPI | |
| SCHEMBL19304403 | 0.84 | BCKDK (0.47) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 | |
| SCHEMBL12896176 | 0.81 | BCKDK (0.38) | BCKDKRAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL16075899 | 0.81 | BCKDK (0.38) | BCKDKRAB9AKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL12310725 | 0.77 | BCKDK (0.56) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 | |
| SCHEMBL31053344 | 0.76 | BCKDK (0.46) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 | |
| SCHEMBL31053377 | 0.75 | BCKDK (0.45) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 | |
| SCHEMBL31053357 | 0.75 | BCKDK (0.45) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 | |
| SCHEMBL12767846 | 0.74 | ALOX5 (0.56) | RAB9AKDM4ESMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL13659611 | 0.73 | BCKDK (0.68) | BCKDKRAB9AKDM4ESENP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-18 | — | — | US | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | BCKDK 4303/4885RAB9A 708/4885KDM4E 248/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | BCKDK 4303/4885RAB9A 708/4885KDM4E 248/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | BCKDK 4303/4885RAB9A 708/4885KDM4E 248/4885 |
| US-20170137425-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | BCKDK 2907/4885RAB9A 1218/4885KDM4E 4325/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | BCKDK 4273/4885RAB9A 693/4885KDM4E 347/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | BCKDK 4303/4885RAB9A 708/4885KDM4E 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.